logo-loader
viewAmphion Innovations PLC

Amphion Innovations chairman and non-executive director step down

The AIM-listed medical, life science and tech business developer said it had begun the process of seeking suitable candidates

Medical Microscope
The news follows the admission to AIM of Amphion’s partner company, Polarean Imaging

Amphion Innovations Plc (LON:AMP) said its chairman, Richard Mansell-Jones, as well as a non-executive director, Miroslaw Izienicki, have stepped down from the board with immediate effect.

The AIM-listed medical, life science and tech business developer said it had begun the process of seeking suitable candidates and would update shareholders accordingly.

READ: Amphion Innovations partner Polarean Imaging begins first day of trading on AIM

Amphion’s chief executive, Richard C.E. Morgan, added: "Our team at Amphion remains confident in the futures of Motif Bio and Polarean Imaging, both now publically listed companies, as well as the future potential of FireStar Software. 

“We believe that as our companies' progress, Amphion's shareholders will benefit in turn and we look forward to building on that base with new investment opportunities in the life-sciences sector."

The news follows the admission to AIM of Amphion’s partner company, Polarean Imaging PLC (LON:POLX) on March 29.

Quick facts: Amphion Innovations PLC

Price: 0.15 GBX

AIM:AMP
Market: AIM
Market Cap: £314.96 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amphion Innovations pinning hopes on Polarean Inc after Motif Bio success

Richard Morgan, chief executive of Amphion PLC (LON:AMP), discusses the 'very welcome' Phase III Iclaprim news from Motif Bio. Motif's recently revealed its lead drug, a next generation antibiotic, successfully negotiated a crucial final-stage clinical study, boosting Amphion’s...

on 10/10/17

2 min read